An observational study in COVID and Corona Virus Infection, sponsored by Egyptian Center for Research and Regenerative Medicine. Completed at 2 sites in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-03-09.
Sponsored by Egyptian Center for Research and Regenerative Medicine · Observational
The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.
929 studies on the registry are indexed under Coronavirus Infections; 50 are open to participants now.
This study's enrollment of 1,546 is above the median of 300 across 334 observational studies indexed under Coronavirus Infections.
Browse Coronavirus Infections studies →This is the only study on the registry with Egyptian Center for Research and Regenerative Medicine as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Age-stratified sample from general population with 3 subgroups:
Exclusion Criteria:
Biological: Specific anti-SARS-CoV-2 antibodies
Biological: Specific anti-SARS-CoV-2 antibodies
Biological: Specific anti-SARS-CoV-2 antibodies
A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples. All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).
Describe the serological status of individuals in the study by presence of specific anti-SARS-CoV-2 antibodies
Time frame: 3 Months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.